Sarcopenia measured by strength, not muscle mass alone, flagged older adults likely to suffer severe cancer treatment toxicity

Design

Secondary analysis of a randomised geriatric assessment trial (usual care arm)

Population

161 adults aged 70 or over with advanced cancer starting new treatment

Primary outcome

Grade 3 to 5 non-haematological toxicity and survival

Effect

Toxicity OR 2.24 (95% CI 1.12 to 4.47); 1-year mortality HR 2.12 (1.14 to 3.93)

A secondary analysis of a geriatric assessment trial in the Journal of Cachexia, Sarcopenia and Muscle (1 October 2026) studied 161 adults aged 70 or over starting a new treatment for advanced cancer in US community oncology practices, using their routine CT scans and a chair-stand test.

Sarcopenia, defined by slow chair stands plus low muscle mass or quality, was present in 57%. It was associated with severe non-haematological toxicity (odds ratio 2.24) and, in those on first-line treatment, with worse one-year survival (46% vs 60%; hazard ratio 2.12). Muscle mass on CT alone was not associated with either outcome.

The sample is small and observational. The useful finding is that strength made the difference: a five-repetition chair stand, which takes a minute in clinic, carried information that a CT measurement on its own did not.

• Time a five-repetition chair stand in older adults before starting cancer treatment.
• Treat slow chair stands (over about 17 seconds) with low muscle mass as a flag for toxicity risk.
• Share sarcopenia findings with the oncology team when treatment intensity is being planned.
• Consider referral for nutrition and resistance exercise support alongside treatment.

Why it matters

It shows a one-minute strength test adds what a CT measurement misses in predicting harm from treatment.

Don't overread it

A small secondary analysis; it does not show that treating sarcopenia reduces toxicity.

The statistics, in plain English

An odds ratio of 2.24 means the odds of severe toxicity were about twice as high with sarcopenia. The interval (1.12 to 4.47) is wide because the sample was small.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.